Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors

Experimental Hematology

Volumn 40, Issue 11, 2012, Pages 882-891.e1

  Pérez Martínez, Antonio ^a   de Prada Vicente, Inmaculada ^a   Fernández, Lucía ^a   González Vicent, Marta ^a   Valentín, Jaime ^a   Martín, Roberto ^a   Maxwell, Hannah ^b   Sevilla, Julián ^a   Vicario, José Luis ^c   Díaz, Miguel ángel ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Grupo de Intervencion en Drogas de la Sociedad Espanola de Medicina Familiar Y Comunitaria   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN A; METHOTREXATE; METHYLPREDNISOLONE; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PACLITAXEL; THIOTEPA; TOPOTECAN; UL16 BINDING PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; DESMOPLASTIC TUMOR; EMBRYONAL RHABDOMYOSARCOMA; EWING SARCOMA; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDENTICAL STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEOPLASM; NEUROBLASTOMA; OUTCOME ASSESSMENT; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SOLID TUMOR; STEM CELL TRANSPLANTATION; TUMOR CELL;

EID: 84867399026     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.07.004     Document Type: Article

References (42)

1. Ladenstein R., Pötschger U., Le Deley M.C., et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010, 28:3284-3291.
2. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
3. Kushner B.H., Meyers P.A. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumour metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001, 19:870-880.
4. Miser J.S., Goldsby R.E., Chen Z., et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumour of bone: evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Goup. Pediatr Blood Cancer 2007, 49:894-900.
5. Ladenstein R., Pötschger U., Hartman O., et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008, 41(suppl 2):S118-S127.
6. Carvallo C., Childs R. Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumours. Cytotechnology 2003, 41:197-206.
7. Childs R.W., Barrett J. Nonmyeloablative allogeneic immunotherapy for solid tumours. Annu Rev Med 2004, 55:459-475.
8. Childs R., Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukaemia at solid tumours. Cancer J 2002, 8:2-11.
9. Lundqvist A., Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumours: current status and future directions. J Immunother 2005, 28:281-288.
10. Ringdén O., Karlsson H., Olsson R., Omazic B., Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147:614-633.
11. Markel G., Seidman R., Besser M.J., et al. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumour activity of allogeneic NK cells. PLoS One 2009, 4:e5597.
12. Igarashi T., Wynberg J., Srinivasan R., et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004, 104:170-177.
13. Lang P., Pfeiffer M., Müller I., et al. Haploidentical stem cell transplantation in patients with paediatric solid tumours: preliminary results of a pilot study and analysis of graft versus tumour effects. Klin Padiatr 2006, 218:321-326.
14. Re F., Staudacher C., Zamai L., Vecchio V., Bregni M. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumours. Cancer 2006, 107:640-648.
15. Pérez-Martínez A., Leung W., Muñoz E., et al. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumour effect in haploidentical stem cell transplantation for paediatric metastatic solid tumours. Pediatr Blood Cancer 2009, 53:120-124.
16. Cao W., He W. UL16 binding proteins. Immunobiology 2004, 209:283-290.
17. Fuertes M.B., Girart M.V., Molinero L.L., et al. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 2008, 180:4606-4614.
18. Chen X.M., Xu X.Q., Sun K., Hallett W.H., Zhao J.D., Zhang D.L. NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells. Scand J Immunol 2008, 67:441-447.
19. Madjd Z., Spendlove I., Moss R., et al. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 2007, 7:17.
20. Verhoeven D.H., de Hooge A.S., Mooiman E.C., et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008, 45:3917-3925.
21. Cho D., Shook D.R., Shimasaki N., Chang Y.H., Fujisaki H., Campana D. Cytotoxicity of activated natural killer cells against paediatric solid tumours. Clin Cancer Res 2010, 16:3901-3909.
22. Sevilla J., González-Vicent M., Lassaletta A., et al. Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. Br J Haematol 2009, 144:909-916.
23. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
24. Chang Y.T., Wu C.C., Shyr Y.M., et al. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One 2011, 6:e20029.
25. Borchers M.T., Harris N.L., Wesselkamper S.C., Vitucci M., Cosman D. NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006, 291:222-231.
26. Blomberg K., Hautala R., Lovgren J., Mukkala V.M., Lindqvist C., Akerman K. Time-resolved fluorometric assay for natural killer activity using target cells labeled with a fluorescence enhancing ligand. J Immunol Methods 1995, 193:199-206.
27. Federmann B., Hägele M., Pfeiffer M., et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukaemia 2011, 25:121-129.
28. Triplett B.M., Horwitz E.M., Iyengar R., et al. Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukaemia 2009, 23:1278-1287.
29. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
30. Pfeiffer M.M., Feuchtinger T., Teltschik H.M., et al. Reconstitution of NK cell receptors influences NK activity and relapse rate after haploidentical transplantation of T and B cell depleted grafts in children. Haematologica 2010, 95:1381-1388.
31. Casado J.G., Pawelec G., Morgado S., et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009, 58:1517-1526.
32. Raffaghello L., Prigione I., Airoldi I., et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004, 6:558-568.
33. Kloess S., Huenecke S., Piechulek D., et al. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol 2010, 40:3255-3267.
34. Stern M., Ruggeri L., Mancusi A., et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008, 112:2990-2995.
35. Han Y., Yu J., Cao S., et al. Fetal-maternal microchimerism enhances the survival effect of interleukin-2-activated haploidentical peripheral blood stem cell treatment in patients with advanced solid cancer. Cancer Biother Radiopharm 2010, 25:741-746.
36. Ballen K.K., Colvin G., Dey B.R., et al. Cellular immune therapy for refractory cancers: novel therapeutic strategies. Exp Hematol 2005, 33:1427-1435.
37. Goodman K.A., Wolden S.L., La Quaglia M.P., Kushner B.H. Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumour. Int J Radiat Oncol Biol Phys 2002, 54:170-176.
38. Basso S., Zecca M., Merli P., et al. T cell therapy for nasopharyngeal carcinoma. J Cancer 2011, 2:341-346.
39. Moretta L., Locatelli F., Pende D., Marcenaro E., Mingari M.C., Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011, 117:764-771.
40. Perez-Martinez A., Iyengar R., Gan K., et al. Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:598-607.
41. Voskens C.J., Watanabe R., Rollins S., Campana D., Hasumi K., Mann D.L. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res 2010, 29:134.
42. Buddingh E.P., Schilham M.W., Ruslan S.E., et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 2011, 60:575-586.